文献速递临床试验与 GCP流行病学与生物统计

SafeBoosC-III试验二次贝叶斯分析的详细统计分析计划:一项评估极早产儿脑氧监测指导治疗与常规护理的多国随机临床试验

Detailed statistical analysis plan for a secondary Bayesian analysis of the SafeBoosC-III trial: a multinational, randomised clinical trial assessing treatment guided by cerebral oximetry monitoring versus usual care in extremely preterm infants.
PubMed 文献 · Trials · 2023-11-16

本文介绍SafeBoosC-III试验的二次贝叶斯分析统计分析计划。该试验为多国、实用型、III期随机临床试验,纳入1601例极早产儿,比较脑氧监测联合治疗指南与常规护理。主要结局为死亡或严重脑损伤的复合结局,贝叶斯分析采用无信息先验,结果以点估计和95%可信区间呈现。

要点

  • SafeBoosC-III试验随机1601例极早产儿,比较脑氧监测指导治疗与常规护理。
  • 主要结局为死亡或严重脑损伤的二分类复合结局。
  • 二次贝叶斯分析采用无信息先验,结果以95%可信区间、贝叶斯因子和临床重要获益或危害概率呈现。

核心结论

  • 该统计分析计划呈现SafeBoosC-III试验的二次贝叶斯分析,将在主要频率学派试验报告发表后进行,以便从频率学派和贝叶斯两种视角解释研究结果。

研究设计与样本

  • SafeBoosC-III试验为研究者发起的、开放标签、随机、多国、实用型、III期临床试验,采用平行组设计,随机1601例极早产儿。
  • 本计划为二次贝叶斯分析的统计分析计划,主要频率学派分析已于2023年4月发表。
  • 主要贝叶斯分析将使用包含所有合理效应的无信息先验。
  • 模型将使用哈密顿蒙特卡洛采样器,1条链,采样10,000次,老化期至少25,000次迭代。

关键数值与推荐

  • 主要结局为死亡或严重脑损伤的二分类复合结局。
  • 探索性结局包括:支气管肺发育不良、早产儿视网膜病变、晚发型败血症、坏死性小肠结肠炎,以及主要新生儿疾病数量(支气管肺发育不良、早产儿视网膜病变和严重脑损伤的计数)。
  • 贝叶斯分析结果将以点估计和95%可信区间(CrIs)呈现,并报告任何获益或危害的概率、贝叶斯因子以及临床重要获益或危害的概率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extremely preterm infants have a high mortality and morbidity. Here, we present a statistical analysis plan for secondary Bayesian analyses of the pragmatic, sufficiently powered multinational, trial-SafeBoosC III-evaluating the benefits and harms of cerebral oximetry monitoring plus a treatment guideline versus usual care for such infants. METHODS: The SafeBoosC-III trial is an investigator-initiated, open-label, randomised, multinational, pragmatic, phase III clinical trial with a parallel-group design. The trial randomised 1601 infants, and the frequentist analyses were published in April 2023. The primary outcome is a dichotomous composite outcome of death or severe brain injury. The exploratory outcomes are major neonatal morbidities associated with neurodevelopmental impairment later in life: (1) bronchopulmonary dysplasia; (2) retinopathy of prematurity; (3) late-onset sepsis; (4) necrotising enterocolitis; and (5) number of major neonatal morbidities (count of bronchopulmonary dysplasia, retinopathy of prematurity, and severe brain injury). The primary Bayesian analyses will use non-informed priors including all plausible effects. The models will use a Hamiltonian Monte Carlo sampler with 1 chain, a sampling of 10,000, and at least 25,000 iterations for the burn-in period. In Bayesian statistics, such analyses are referred to as 'posteriors' and will be presented as point estimates with 95% credibility intervals (CrIs), encompassing the most probable results based on the data, model, and priors selected. The results will be presented as probability of any benefit or any harm, Bayes factor, and the probability of clinical important benefit or harm. Two statisticians will analyse the blinded data independently following this protocol. DISCUSSION: This statistical analysis plan presents a secondary Bayesian analysis of the SafeBoosC-III trial. The analysis and the final manuscript will be carried out and written after we publicise the primary frequentist trial report. Thus, we can interpret the findings from both the frequentists and Bayesian perspective. This approach should provide a better foundation for interpreting of our findings. TRIAL REGISTRATION: ClinicalTrials.org, NCT03770741. Registered on 10 December 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Olsen MH, Hansen ML, Lange T, et al. Detailed statistical analysis plan for a secondary Bayesian analysis of the SafeBoosC-III trial: a multinational, randomised clinical trial assessing treatment guided by cerebral oximetry monitoring versus usual care in extremely preterm infants. Trials. 2023. PMID: 37974280. doi:10.1186/s13063-023-07720-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。